RESEARCH PAPER
Effect of cycloporine A administration on aminothiols plasma concentration in children with idiopathic nephrotic syndrome
 
More details
Hide details
1
Klinika Pediatrii i Immunologii z Pododdziałem Nefrologii, Instytut Centrum Zdrowia Matki Polki w Łodzi,
2
Zakład Chemii Środowiska Uniwersytetu Łódzkiego
3
Klinika Hematologii, Onkologii i Diabetologii Dziecięcej, Uniwersytet Medyczny w Łodzi
CORRESPONDING AUTHOR
Marcin Tkaczyk
Klinika Pediatrii i Immunologii z Pod- Opinie o tym, czy ZN w dzieciństwie podobnie wpływa na oddziałem Nefrologii, Instytutu Centrum Zdrowia Matki Polki w Łodzi, ul Rzgowska 281/289, 93-338 Łódź
 
Med Og Nauk Zdr. 2013;19(1):59–63
 
KEYWORDS
ABSTRACT
Introduction:
Assessment of changes in plasma aminothiols metabolism in idiopathic nephrotic syndrome (INS) in children, with special consideration of the influence of cyclosporine A administration. Aminothiols are important elements of the red-ox balance in humans. The imbalance in red-ox status has been described in the nephrotic syndrome but may be a result of the disease itself or treatment (cyclosporine A).

Material and Methods:
The study group covered 95 nephrotic children divided into 3 groups, i.e. in acute phase of the disease (30), during steroid-induced (37), and steroid-free remission (28). In each group, children treated with Cyclosporine A were selected for the study, and a control group of 32 healthy children. Aminothiols in plasma were assessed by high-performance liquid chromatography. Protein bound and free fractions of aminothiols were measured.

Results:
Concentration of cysteine and homocysteine in nephrotic children were similar to controls. Only a few changes between stages of the disease were found. Free (toxic) homocysteine was elevated in early remission of INS. Glutathione concentration was not changed, whereas cysteinyloglycine concentration was decreased in first two stages of INS. Children treated with cyclosporine A showed significantly higher homocysteine and cysteine plasma concentrations in relapse and early remission of INS.

Conclusions:
Cyclosporine A may have a detrimental effect on the concentration of aminothiols promoting atherogenesis; however, the clinical importance of these observations requires further studies.

 
REFERENCES (27)
1.
Fydryk J, Jacobson E, Kurzawska O, Małecka G, Gonet B, Urasinski T, Broskiewicz A, Bukowska A. Antioxidant status of children with steroid sensitive nephrotic syndrome. Pediatr Nephrol. 1998; 12: 751–754.
 
2.
Hermann A, Mannitius J, Rutkowski B. Homocysteina w chorobach nerek. Nefrol Dial Pol. 2000; 4: 10–13.
 
3.
Turi S, Nemeth I, Torkos A, Saghy L, Varga I, Matkovics B, Nagy J: Oxidative stress and antioxidant defense mechanism in glomerular diseases. Free Radic Biol Med. 1997; 22: 161–168.
 
4.
Skrzep-Poloczek B, Tomasik A, Tarnawski R, Hyla-Klekot L, Dyduch A,Wojciechowska C, Wesolowski W, Kopieczna Grzebieniak E, Zalejska- -Fiolka J, Widera E. Nephrotic origin hyperlipidemia, relative reduction of vitamin E level and subsequent oxidative stress may promote atherosclerosis. Nephron. 2001; 89: 68–72.
 
5.
Dogra GK, Irish AB, Watts GF. Homocysteine and nephrotic syndrome. Nephrol Dial Transplant. 2001; 16: 1720–1721.
 
6.
Arnadottir M, Hultberg B, Berg AL. Plasma total homocysteine concentration in nephrotic patients with idiopathic membranous nephropathy. Nephrol Dial Transplant. 2001; 16: 1720–1721.
 
7.
Podda GM, Lussana F, Moroni G, Faioni EM, Lombardi R, Fontana G, Ponticelli C, Maioli C, Cattaneo M. Abnormalities of homocysteine and B vitamins in the nephrotic syndrome. Thromb Res. 2007; 120: 647–652.
 
8.
Tkaczyk M, Czupryniak A, Nowicki M, Chwatko G, Bald E. Homocysteine and glutathione metabolism in steroid-treated relapse of idiopathic nephrotic syndrome. Pol Merkur Lek. 2009; 26: 294–297.
 
9.
Dairou F. Lipid disorders and cardiovascular risk in nephrology. Nephrol Dial Transplant. 1998; 13: 30–33.
 
10.
Socha MW, Polakowska MJ, Socha-Urbanek K, Fiedor P. Hyperhomocysteinemia as a risk factor for cardiovascular diseases. The association of hyperhomocysteinemia with diabetes mellitus and renal transplant recipients. Ann Transplant. 1999; 4: 11–19.
 
11.
Massy ZA. Importance of homocysteine, lipoprotein (a) and non- -classical cardiovascular risk factors (fibrinogen and advanced glycation end-product) for atherogensesis in uraemic patients. Nephrol Dial Transplant. 2000; 15: 81–89.
 
12.
International Study of Kidney Diseases in Children: Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int. 2005; 20: 765–777.
 
13.
Chwatko G, Bald E. Determinination of different species of homocysteine in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatography 2002; 949: 141–151.
 
14.
Yi F, Li PL: Mechanisms of Homocysteine-Induced Glomerular Injury and Sclerosis. Am J Nephrol. 2008; 28: 254–264.
 
15.
Tenderenda E, Korzeniecka-Kozerska A, Porowski T, Wasilewska A, Zoch-Zwierz W. Stężenie homocysteiny w osoczu i moczu u dzieci ze steroidozależnym zespołem nerczycowym. Pol Merkur Lek. 2011; 31: 204–208.
 
16.
Berg AL, Rafnsson AT, Johannsson M, Hultberg B, Arnadottir M. The effects of adrenocorticotrophic hormone and cortisol on homocysteine and vitamin B concentrations. Clin Chem Lab Med. 2006; 44: 628–631.
 
17.
Libetta C, Sepe V, Zucchi M, Pisacco P, Portalupi V, Adamo G, Soccio G, Dal Canton A. Influence of methylprednisolone on plasma homocysteine levels in cadaveric renal transplant recipients. Transplant Proc. 2006; 38: 2893–2894.
 
18.
Kniazewska MH, Obuchowicz AK, Wielkoszynski T, Zmudzinska- -Kitczak J, Urban K, Marek M, Witanowska J, Sieron-Stoltny K. Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome. Pediatr Nephrol. 2009; 24: 549–554.
 
19.
Belson A, Sanchez J, Alexander SR, Salvatierra O, Dar MH, Reif S, Yorgin PD. Hyperhomocysteinemia in pediatric and young adult renal transplant recipients. Pediatr Transplant. 2004; 8: 161–166.
 
20.
Einollahi B, Lessan-Pezeshki M, Kalantar E, Rostami Z, Khalili N, Ghadiani MH, Ahmadi J. Hyperhomocysteinemia after kidney transplantation. Transplant Proc. 2011; 43: 586–587.
 
21.
Böhmer AE, Brum LM, Souza DG, Correa AM, Oses JP, Viola GG, Saraiva PJ, Driemeier D, Portela LV, Souza DO. Chronic treatment with cyclosporine affects systemic purinergic parameters, homocysteine levels and vascular disturbances in rats. Chem Biol Interact. 2010; 188: 15–20.
 
22.
Can C, Erol A, Olukman M, Cinar MG, Ulker S. Vascular endothelial dysfunction in cyclosporine-treated rat aortas is not associated with serum total homocysteine levels. Transplant Proc. 2008; 10: 3702–3706.
 
23.
Fydryk J, Olszewska M, Urasinski T, Brodkiewicz A. Serum selenium level and glutathione peroxidase activity in steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2003; 18: 1063–1065.
 
24.
Granqvist A, Nilsson UA, Ebefors K, Haraldsson B, Nystrom J. Impaired glomerular and tubular antioxidative defense mechanisms in nephrotic syndrome. Am J Physiol Renal Physiol. 2010; 299: F898-F904.
 
25.
Hultberg B, Andersson A, Arnadottir M. Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron. 1995; 70: 62–67.
 
26.
Dogra GK, Herrmann S, Irish AB, Thomas MAB, Watts GF. Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. Nephrol Dial Transplant. 2002; 17: 2220–2225.
 
27.
Kniazewska MH, Obuchowicz AK, Wielkoszynski T, Zmudzinska- -Kitczak J, Urban K, Hyla-Klekot L. Evaluation of certain constituents of antioxidant defense in youth treated in the past for steroid-sensitive idiopathic nephrotic syndrome. Pediatr Nephrol. 2009; 24: 2187–2192.
 
eISSN:2084-4905
ISSN:2083-4543